Transplantation of Hematopoietic Stem Cells in Tumor Therapy
DOI:
https://doi.org/10.62051/2v4ts794Keywords:
HSCT; cancer; immune therapy; GVHD; transplant-related mortality.Abstract
Hematopoietic stem cell transplantation therapy (HSCT) has achieved remarkable results in the treatment of various malignant tumors, especially leukemia and other hematologic diseases. However, it still faces some problems in clinical application. They mainly include graft-versus-host disease (GVHD), transplantation-related mortality (TRM), difficulties in donor matching, risk of disease recurrence, and high treatment costs and technical requirements. However, with the recent development of hemi-compatible donor and cord blood transplantation technology and the advancement of GVHD prevention and treatment technology, HSCT is on the way to becoming safer and more efficient, but how to ensure the efficacy while reducing the consequences of complications is still an important direction for future research.
Downloads
References
[1] Qin, Y. Research progress in early screening of hepatocellular carcinoma by circulating tumor cell. Journal of Modern Oncology, 2022, 30(06): 1133-1137.
[2] Hausman, D. M. What is cancer? Perspectives in Biology and Medicine, 2019, 62(4): 778-784.
[3] Hall, V. G., & Teh, B. W. COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: Immune response, real-world effectiveness, and implications for the future. The Journal of Infectious Diseases, 2023, 228(Suppl 1): S55-S69.
[4] Appelbaum, F. R. Hematopoietic-cell transplantation at 50. The New England Journal of Medicine, 2007, 357(15): 1472-1475.
[5] Chusri, P., & Chirathaworn, C. Immunotherapy and hematopoietic stem cell transplantation for hepatocellular carcinoma: Emerging roles and future directions. Frontiers in Immunology, 2021, 12: 673295.
[6] Younis M. A., Harashima H., Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine. Pharmacogenomics and personalized medicine, 2024: 193-213.
[7] Nieto, Y., Nawrocki, S. T., & Champlin, R. E. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for solid tumors other than breast cancer and germ cell tumors. Cancer Treatment Reviews, 2001, 27(4): 235–256.
[8] Zhao, Y., Qiao, D., Shi, C., et al. Application of mesenchymal stem cell-based therapy for lung cancer: Progress and challenges. Frontiers in Oncology, 2021, 11: 769194.
[9] Bregni, M., & Siena, S. Allogeneic transplantation for solid tumors: A realistic treatment option? Current Opinion in Oncology, 2001, 13(2): 102-107.
[10] Yin, G., Li, J., Miao, K., Progress on graft failure of allogeneic hematopoietic stem cell transplantation. Journal of Nanjing Medical University (Natural Sciences), 2020, 40(01): 141-146+150.
[11] Passweg, J. R., Baldomero, H., Bader, P., et al. Hematopoietic stem cell transplantation in Europe 2019: Trends and developments. Bone Marrow Transplantation, 2021, 56(3): 537-548.
[12] Zeiser, R., & Blazar, B. R. Acute graft-versus-host disease—Biologic process, prevention, and therapy. New England Journal of Medicine, 2017, 377(22): 2167-2179.
[13] Eskandari S K, Revenich E G M, Pot D J, et al. High-dose ert, rituximab, and early hsct in an infant with wolman’s disease. New England Journal of Medicine, 2024, 390(7): 623-629.
[14] Versluis J, Saber W, Tsai H K, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. Journal of Clinical Oncology, 2023, 41(28): 4497-4510.
[15] Bacigalupo A, Sormani M P, Lamparelli T, et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica, 2004, 89(10): 1238-1247.
[16] Mehta P A, Davies S M. Allogeneic transplantation for childhood ALL. Bone marrow transplantation, 2008, 41(2): 133-139.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
